B&L Retisert Drug Delivery Implant FDA Filing Delayed By One Year
This article was originally published in The Gray Sheet
Executive Summary
Bausch & Lomb will wait for results from its second pivotal trial for the Retisert drug-delivery implant for treating posterior uveitis before submitting a new drug application to FDA, which is expected in mid-2004
You may also be interested in...
B&L Expanded Drug-Delivery Products Seen As Springboard To Future Growth
Bausch & Lomb continues to transform itself into a drug-delivery eyecare company from a traditional contact lens firm, with implants and molecular compounds in various stages of development
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.